Much effort has been devoted to developing potent and selective H3R inhibitors (antagonists/inverse agonists) [3,4,5], and pitolisant (2, Figure 1) was recently authorized in Europe as a medicine for treating narcolepsy with or without cataplexy [6]. The gene discussed is HRH3; the disease is narcolepsy.